Sanofi SA

SNY

47.030USD

-0.620-1.30%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

59 / 176

Overall Ranking

178 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

63.674

Target Price

+35.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.

Undervalued

The company’s latest PE is 11.71, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 264.33M shares, decreasing 5.11% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 71.72M shares of this stock.

The company's current financial score is 8.33, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 11.15B, representing a year-over-year increase of 5.58%, while its net profit experienced a year-over-year increase of 59.98%.

Score

Industry at a Glance

Previous score

8.33

Change

0



Financials

8.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.05

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.61

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 12.48, which is 80.54% below the recent high of 22.53 and -18.69% above the recent low of 14.81.

Score

Industry at a Glance

Previous score

1.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/176

No Data

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Sanofi SA is 64.97, with a high of 74.67 and a low of 56.00.

Score

Industry at a Glance

Previous score

8.20

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.21, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 52.90 and the support level at 46.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

-0.04

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 10.86%, representing a quarter-over-quarter increase of 2.23%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 71.72M shares, representing 2.95% of shares outstanding, with 1.05% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

73.19M

-2.70%

Fisher Investments

Star Investors

13.57M

+8.43%

Invesco Advisers, Inc.

11.37M

-0.03%

Capital World Investors

8.32M

--

Managed Account Advisors LLC

7.57M

-2.22%

Barrow Hanley Global Investors

Star Investors

7.35M

-4.52%

T. Rowe Price Associates, Inc.

Star Investors

11.03M

+1.78%

Wellington Management Company, LLP

4.43M

-1.27%

Putnam Investment Management, L.L.C.

3.72M

+18.23%

Boston Partners

4.09M

-24.22%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.79, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Sanofi SA

SNY

6.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.